Dwight Owens, MD
Psychiatry · Atlanta, GANPI 1518989433
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,150 of the $23,880 with a category attached, or 88.6%. AbbVie accounts for 89.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $10,965 and has fallen 96.4% since, to $389 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $346.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Neuronetics, Inc.$2K
- Tris Pharma Inc$218
- Teva Pharmaceuticals USA, Inc.$125
- Otsuka America Pharmaceutical, Inc.$113
- Novo Nordisk$100
- plus $221 from 6 others
What the payments were for
- Speaking & faculty fees$21,15089%
- Travel & lodging$1,0344%
- Food & beverage$1,6967%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $21,471 |
| Neuronetics, Inc. | 3 | $1,633 |
| Tris Pharma Inc | 11 | $218 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 6 | $113 |
| Novo Nordisk | 1 | $100 |
| Johnson & Johnson | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| Shire North American Group Inc | 2 | $39 |
| Bioxcel Therapeutics, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$21,150
- NEUROSTAR TMS THERAPY SYSTEM$1,621
- UZEDY$125
How this compares
$23,880 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 26 | $5,735 |
| Bupropion XlBupropion Hcl | 13 | $324 |
| Escitalopram Oxalate | 35 | $239 |
| Quetiapine Fumarate | 12 | $210 |
| Mirtazapine | 20 | $125 |
| Haloperidol | 11 | $119 |
| Clonazepam | 51 | $61 |
| Buspirone Hcl | 13 | $40 |
| Alprazolam | 12 | $9 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Atlanta
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Ray HorwitzAtlanta$64K
- Boadie DunlopAtlanta$61K
- Zohaib HaqueAtlanta$49K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.